## Review setup
- **Input scope** Abstract only
- **Assessment boundary** Claims and evidence as presented in the abstract; no access to methods, figures, tables, or supplementary materials
- **Shared manuscript claim summary** The authors present LMEFold, a protein language model-based deep learning framework that predicts early folding residues (EFRs) from amino acid sequence. They report benchmark performance on Start2Fold (ROC AUC = 0.831), association with HDX-NMR protection factors, enrichment of ClinVar pathogenic variants in EFRs (~17%) versus population variants (~10%, P < 0.001), and association of EFR mutations with reduced survival in the MSK-MET pan-cancer cohort. A structural mechanism is proposed for TP53 p.Y163C.
- **Visible evidence base** Abstract text only; no figures, tables, methods, or supplementary data provided
- **Missing materials affecting confidence** Full methods, model architecture and training details, benchmark evaluation protocol, statistical analysis details, survival analysis methodology, variant annotation pipeline, structural analysis procedures, and all underlying data

## Reviewer
- **Overall assessment** The abstract presents a potentially interesting application of protein language models to a biologically relevant problem, namely the identification of early folding residues and their relationship to pathogenic variants. The core claims are plausible but cannot be adequately evaluated from the abstract alone. Several critical methodological details are absent, including how EFRs are defined, how the model is trained and validated, and how the statistical associations are computed. The survival analysis claim is particularly under-specified. The work may be of interest to the protein folding and clinical genomics communities, but the evidence base provided is insufficient to establish the case.
- **Who would be interested in the results, and why** Researchers in protein folding, protein stability, and misfolding diseases would be interested in the EFR prediction framework and its biophysical validation. Clinical genomics researchers and those working on variant interpretation and cancer prognosis may find the association between EFR mutations and patient survival relevant. The use of protein language models for sequence-only prediction may also appeal to the computational biology and machine learning communities.
- **Major strengths** The problem addressed is of clear biological and clinical importance. The use of protein language models for sequence-only prediction is timely and potentially scalable. The abstract reports validation against independent biophysical measurements (HDX-NMR) and large-scale genomic datasets, which strengthens the credibility of the approach. The proposed mechanism for TP53 p.Y163C provides a concrete example that could be experimentally testable.
- **Major Concerns** 
  - R1-M1
  - R1-M2
  - R1-M3
  - R1-M4
- **Minor Comments** 
  - R1-m1
  - R1-m2
  - R1-m3
- **Technical failings that need to be addressed before the case is established** R1-M1 (EFR definition and model validation), R1-M2 (statistical comparison of variant enrichment), R1-M3 (survival analysis methodology), R1-M4 (structural mechanism evidence)
- **Assessment against Nature-style criteria** Originality: The concept of linking EFRs to pathogenic variants is not entirely new, but the use of PLMs for proteome-wide EFR prediction may offer a novel computational contribution. Scientific importance: If the claims are substantiated, the work could have implications for variant interpretation and cancer prognosis, which is of high importance. Interdisciplinary readership: The work spans protein biophysics, computational biology, and clinical genomics, which could attract a broad audience. Technical soundness: Cannot be assessed from the abstract alone; the reported AUC of 0.831 is modest and requires careful benchmarking. Readability for nonspecialists: The abstract is generally clear, though some terms (e.g., HDX-NMR protection factors) may require background knowledge.
- **Recommendation posture** Currently not established from the provided evidence. The abstract presents interesting hypotheses and preliminary associations, but the lack of methodological detail and the under-specified statistical and clinical analyses prevent a supportive recommendation. The authors should provide full methods and results for a complete evaluation.

### Major Concerns

- **Concern ID** R1-M1
- **Severity** Major
- **Blocking** Yes
- **Axis** Technical soundness
- **Claim pointer** "LMEFold outperforms existing sequence-based predictors on the Start2Fold benchmark (ROC AUC = 0.831)"
- **Evidence pointer** Abstract only; location not provided
- **Concern** The abstract does not define what constitutes an early folding residue, nor does it describe the training and validation protocol for LMEFold. The reported ROC AUC of 0.831 is presented as evidence of superior performance, but no comparison details are given, such as which predictors were compared, whether the comparison was statistically significant, and how the benchmark was split for training and testing. Without this information, the claim of outperformance cannot be evaluated.
- **Why it matters** The central contribution of the work is the prediction framework. If the model's performance is not rigorously established, all downstream analyses that depend on predicted EFRs are compromised.
- **Resolution test** Provide a clear definition of EFRs, describe the model architecture and training data, and report a full benchmark evaluation including statistical significance tests against multiple baseline predictors on held-out test sets.

- **Concern ID** R1-M2
- **Severity** Major
- **Blocking** Yes
- **Axis** Statistical rigor
- **Claim pointer** "pathogenic mutations curated in ClinVar are significantly enriched within EFRs (~17%) compared to millions of population variants from large-scale cohorts including the UKB and gnomAD databases (~10%, P < 0.001)"
- **Evidence pointer** Abstract only; location not provided
- **Concern** The abstract reports a comparison between ClinVar pathogenic variants and population variants from UKB and gnomAD, but it does not specify how the comparison was performed. Critical details are missing, including whether the variant sets were matched for confounding factors such as gene size, mutation type, or regional sequence context, and how the P value was calculated. The use of "millions of population variants" as a comparator raises concerns about the appropriateness of the statistical test and the potential for inflated significance due to large sample sizes.
- **Why it matters** The enrichment claim is a key finding that links EFRs to pathogenicity. If the statistical comparison is flawed or confounded, the conclusion that EFRs are "critical hotspots" for pathogenic variants is not supported.
- **Resolution test** Describe the exact statistical test used, report effect sizes and confidence intervals, and demonstrate that the enrichment is robust to confounding factors such as gene length, variant type, and mutational heterogeneity across genes.

- **Concern ID** R1-M3
- **Severity** Major
- **Blocking** Yes
- **Axis** Clinical validity
- **Claim pointer** "in the MSK-MET pan-cancer clinical cohort, EFR mutations are associated with severe functional disruption and significantly reduced overall patient survival"
- **Evidence pointer** Abstract only; location not provided
- **Concern** The survival analysis is described in a single sentence with no methodological detail. It is unclear how EFR mutations were defined in the cohort, which cancer types were included, how the survival analysis was performed (e.g., Cox proportional hazards model), what covariates were adjusted for, and what the effect size and confidence intervals were. The claim of "severe functional disruption" is also not defined or quantified.
- **Why it matters** The clinical relevance of the work rests on this survival association. Without proper survival analysis methodology and reporting, the claim of reduced patient survival is not credible.
- **Resolution test** Provide a detailed description of the cohort, the definition of EFR mutations, the survival analysis model, covariates, and report hazard ratios with confidence intervals and P values. Also define and quantify "functional disruption" with appropriate assays or computational predictions.

- **Concern ID** R1-M4
- **Severity** Major
- **Blocking** No
- **Axis** Mechanistic evidence
- **Claim pointer** "Structural analysis of hotspot cancer mutations, such as TP53 p.Y163C, suggests a mechanism whereby these variants destabilize protein structure by disrupting the early folding core"
- **Evidence pointer** Abstract only; location not provided
- **Concern** The abstract claims a mechanistic explanation for TP53 p.Y163C based on structural analysis, but no details are provided on the structural data, the analysis method, or how the disruption of the early folding core is demonstrated. The word "suggests" indicates a hypothesis, but the evidence base is not described.
- **Why it matters** A mechanistic claim strengthens the biological relevance of the work, but without supporting structural or experimental evidence, it remains speculative.
- **Resolution test** Provide structural models or experimental data (e.g., molecular dynamics simulations, mutagenesis, or biophysical measurements) that directly demonstrate destabilization of the folding core by p.Y163C and other hotspot mutations.

### Minor Comments

- **Concern ID** R1-m1
- **Severity** Minor
- **Axis** Clarity
- **Affected element** Abstract terminology
- **Evidence pointer** Abstract; location not provided
- **Issue** The term "early folding residues" is used throughout but is not defined in the abstract. Readers unfamiliar with the folding literature may not understand what this means.
- **Required correction** Provide a brief definition or description of EFRs in the abstract, such as "residues that initiate the folding process and form the folding nucleus."

- **Concern ID** R1-m2
- **Severity** Minor
- **Axis** Completeness
- **Affected element** Dataset description
- **Evidence pointer** Abstract; location not provided
- **Issue** The abstract mentions "diverse genomic datasets" and "large-scale cohorts including the UKB and gnomAD" but does not specify the number of variants or the criteria for inclusion.
- **Required correction** Include the total number of variants analyzed and a brief description of the datasets and filtering criteria.

- **Concern ID** R1-m3
- **Severity** Minor
- **Axis** Reproducibility
- **Affected element** Model availability
- **Evidence pointer** Abstract; location not provided
- **Issue** The abstract does not state whether the LMEFold model or its code will be made publicly available, which is important for reproducibility and community use.
- **Required correction** State the availability of the model, code, and any associated web server or repository.

## Risk / unsupported claims
- The claim that LMEFold "outperforms existing sequence-based predictors" is unsupported without detailed benchmark comparison data.
- The enrichment of pathogenic variants in EFRs is reported with a P value but without effect size or confidence intervals, making the practical significance unclear.
- The survival association in the MSK-MET cohort is not supported by any methodological detail and cannot be evaluated.
- The mechanistic claim for TP53 p.Y163C is speculative and lacks supporting structural or experimental evidence.
- The general statement that EFRs are "critical sites of pathogenic vulnerability" is a broad conclusion that extends beyond the specific findings reported in the abstract.